Join
Live feed
·
INSIDERFilingvia Quantisnow
Rapport Therapeutics Inc. logo

Chief Development Officer Yeleswaram Krishnaswamy was granted 9,000 shares and sold $85,342 worth of shares (2,840 units at $30.05), increasing direct ownership by 2% to 296,991 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RAPP· Rapport Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPP (Rapport Therapeutics Inc.) and more on Quantisnow.